**Clinical Decision Aids and Computed Tomography Coronary Angiography in Patients with Suspected Acute Coronary Syndrome**

**A secondary analysis of the RAPID-CTCA trial**

**Running title:** Test performance in intermediate-risk ACS

Kang-Ling Wang, MD,1,2,3 Caelan Taggart, MD,1 Michael McDermott, MD,1 Rachel O’Brien, BN,4 Katherine Oatey, BSc,5 Liza Keating, MB ChB,6 Robert F Storey, MD,7,8 Dirk Felmeden, MD,9 Nick Curzen, BM, PhD,10,11 Attila Kardos, MD, PhD,12,13 Carl Roobottom, MD, PhD,14,15 Jason E Smith, MD,16 Steve Goodacre, MB ChB, PhD,17 David E Newby, MD, PhD,1 and Alasdair J Gray, MB ChB,4,18 on behalf of the RAPID-CTCA Investigators

1 Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

2 School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

3 General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan

4 Department of Emergency Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

5 Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, United Kingdom

6 Department of Emergency Medicine, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom

7 Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom

8 NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

9 Department of Cardiology, Torbay and South Devon NHS Foundation Trust, Torquay, United Kingdom

10 Faculty of Medicine, University of Southampton, Southampton, United Kingdom

11 Department of Cardiology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

12 Department of Cardiology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, United Kingdom

13 Faculty of Medicine and Health Science, University of Buckingham, Buckingham, United Kingdom

14 Department of Radiology, University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom

15 Faculty of Health, University of Plymouth, Plymouth, United Kingdom

16 Emergency Department, University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom

17 Division of Population Health, University of Sheffield, Sheffield, United Kingdom

18 Usher Institute, University of Edinburgh, Edinburgh, United Kingdom

**Correspondence**

Dr Kang-Ling Wang

Centre for Cardiovascular Science

University of Edinburgh

Chancellor’s Building

49 Little France Crescent

Edinburgh EH16 4SB

United Kingdom

k.l.wang@ed.ac.uk

**Disclosure**

We have no competing interests related to this manuscript to disclose.

Katherine Oatey reports research grants from the British Heart Foundation, the Jon Moulton Charity Trust, and University of Edinburgh.

Liza Keating reports research grants from the Medical Research Council Developmental Pathway Funding Scheme and the Royal College of Emergency Medicine.

Robert F Storey reports research grants from AstraZeneca and Cytosorbents; consulting fees and/or honoraria from Alfasigma, AstraZeneca, Chiesi, Cytosorbents, Daiichi-Sankyo, Idorsia, Novartis, Novo Nordisk, Pfizer, PhaseBio, and Tabuk.

Nick Curzen reports research grants from Beckman Coulter, Boston Scientific, HeartFlow, and Haemonetics; consulting fees and/or honoraria from Abbott, Boston Scientific, and Edwards Lifesciences; travel sponsorship from Abbott, Biosensors, and Edwards Lifesciences.

Attila Kardos reports honoraria from the TomTec Imaging Systems.

Carl Roobottom reports honoraria from GE HealthCare.

Word Count: 2949 (excluding figure legends and references)

Reference Count: 30

Table Count: 2

Figure Count: 4

Supplementary Document: 1

**Abstract**

**Background**

The HEART score, the T-MACS model, and the GRACE score support early decision making for acute chest pain, which could be complemented by computed tomography coronary angiography (CTCA). However, their performance has not been directly compared.

**Methods**

In this secondary analysis of a multicentre randomised controlled trial of early CTCA in intermediate-risk patients with suspected acute coronary syndrome, *C*-statistics and performance metrics (using the pre-defined cutoffs) of clinical decision aids and CTCA, alone and then in combination, for the index hospital diagnosis of acute coronary syndrome and for 30-day coronary revascularisation were assessed in those who underwent CTCA and had complete data.

**Results**

Amongst 699 patients, 358 (51%) had an index hospital diagnosis of acute coronary syndrome, for which the *C*-statistic was higher for CTCA (0.80), followed by the T-MACS model (0.78), the HEART score (0.74), and the GRACE score (0.60). The negative predictive value was higher for the absence of coronary artery disease on CTCA (0.90) or a T-MACS estimate of <0.05 (0.83) than a HEART score of <4 (0.81) and a GRACE score of <109 (0.55). For 30-day coronary revascularisation, CTCA had the greatest *C*-statistic (0.80) with a negative predictive value of 0.96 and 0.92 in the absence of coronary artery disease and obstructive coronary artery respectively. The combination of the T-MACS estimates and the CTCA findings was most discriminative for the index hospital diagnosis of acute coronary syndrome (*C*-statistic, 0.88) and predictive of 30-day coronary revascularisation (*C*-statistic, 0.85). No patients with a T-MACS estimate of <0.05 and normal coronary arteries had acute coronary syndrome during index hospitalisation or underwent coronary revascularisation within 30 days.

**Conclusions**

In intermediate-risk patients with suspected acute coronary syndrome, the T-MACS model combined with CTCA improved discrimination of the index hospital diagnosis of acute coronary syndrome and prediction of 30-day coronary revascularisation.

**Keywords**

Acute coronary syndrome, clinical decision aid, computed tomography coronary angiography.

Word Count: 300

**What is already known on this topic**

* Clinical decision aids—the HEART score, the T-MACS model, and the GRACE score—and computed tomography coronary angiography (CTCA) have been adopted into clinical practice to risk stratify patients with acute chest pain.
* Their performance for diagnosis and prognosis in intermediate-risk patients with suspected acute coronary syndrome has not previously been directly compared.

**What this study adds**

* The HEART score, the T-MACS model, and CTCA were more discriminative for the index hospital diagnosis of acute coronary syndrome than the GRACE score, and CTCA was most predictive of 30-day coronary revascularisation.
* The combination of the T-MACS estimates and the CTCA findings had the best diagnostic and prognostic performance for acute coronary syndrome during index hospitalisation and coronary revascularisation within 30 days.

**How this study might affect research, practice, or policy**

* The T-MACS model combined with CTCA could be used to assist diagnosis, guide management, and improve prognostication in patients with intermediate-risk chest pain due to suspected acute coronary syndrome.
* This may expedite the patient journey in the emergency department and facilitate patient selection for invasive coronary angiography.

**Introduction**

Acute chest pain is one of the leading reasons for seeking emergency care. The aims of initial clinical assessment are to ‘rule out’ or to ‘rule in’ acute coronary syndrome and to differentiate other life-threatening diagnoses like acute aortic syndrome or pulmonary embolism from other less time-sensitive conditions.[1] To support early decision making in this heterogeneous patient population, multiple clinical decision aids have been developed.

The contemporary European Society of Cardiology clinical decision aids are based on serial high-sensitivity cardiac troponin testing and can ‘rule out’ and ‘rule in’ myocardial infarction in approximately 60% and 15% of all patients presenting to emergency departments respectively.[2] This leaves 1 in 4 patients assigned to the ‘observe’ pathway or the ‘intermediate risk’ category.[3, 4] in which the spectrum of final diagnoses could range from an undetermined aetiology to myocardial infarction. Their distinction has therapeutic implications, as preventative treatment and coronary revascularisation are more likely to benefit those with coronary artery disease.

Clinical decision aids, such as the HEART score,[5] the T-MACS model,[6] and the GRACE score,[7] have been developed as risk stratification tools that are less constrained by the requirement of high-sensitivity cardiac troponin testing and repeated sampling for cardiac troponin. However, they are not specifically designed to address the uncertainty in patients at intermediate risk, who often have multiple cardiovascular risk factors, pre-existing atherosclerotic disease, or an ischaemic electrocardiogram (ECG).[8, 9] This can lead to the requirement for additional investigations to refine clinical decision making.[10]

Whilst discriminating myocardial infarction and unstable angina is essential during initial clinical assessment, identifying the presence of coronary artery disease continues to be vital for clinical decision making. This can be readily assessed by computed tomography coronary angiography (CTCA), which clarifies the need for interventional treatment and out-patient review, thereby improving future prognosis.[11, 12] Nevertheless, the effectiveness of clinical decision aids and CTCA in diagnosis, management, and prognostication of patients with suspected acute coronary syndrome has never been directly compared. The combined strength of the estimated clinical risk and the knowledge of coronary artery anatomy could potentially have synergistic benefits.

The Rapid Assessment of Potential Ischaemic Heart Disease with CTCA (RAPID-CTCA) trial evaluated the effectiveness of early CTCA in intermediate-risk patients with suspected acute coronary syndrome and has reported that early CTCA did not further improve 1-year clinical outcomes.[13] In this secondary analysis, we aimed to assess the diagnostic and prognostic performance of the HEART score, the T-MACS model, the GRACE score, and CTCA, alone and then in combination, for the index hospital diagnosis of acute coronary syndrome and 30-day coronary revascularisation.

**Method**

*Trial overview*

The RAPID-CTCA trial (ClinicalTrials.gov identifier, NCT02284191) was a prospective randomised open-label blinded endpoint trial conducted at 37 sites across the United Kingdom between March 2015 and June 2019. Patients presenting to an emergency department or hospital admission facilities with intermediate-risk chest pain due to suspected acute coronary syndrome, defined by having either a history of coronary artery disease, an abnormal ECG, or an elevated cardiac troponin concentration, were randomised to receive early CTCA in addition to standard of care or standard of care only.

The trial was conducted with the approval of the South East Scotland Research Ethics Committee (14/SS/1096). All patients gave written informed consent.

*Clinical gestalt and cardiac troponin testing*

Before randomisation, treating physicians were asked to use a 3-point Likert scale to grade their perceived probability of acute coronary syndrome of every patient during initial clinical assessment.

Cardiac troponin was measured in local accredited clinical biochemistry laboratories according to standard clinical practice at each site, where assays and local laboratory reference standards varied. The overall cutoffs according to manufacturers were used to standardise the level of cardiac troponin in the current study (Supplementary Table 1). Because not all patients underwent repeated cardiac troponin testing or had the complete profile of serial cardiac troponin measurements recorded, we only used their cardiac troponin concentration at presentation.

*Study design*

The current study population included individuals who underwent CTCA with a complete dataset for CTCA and the three selected clinical decision aids, as we wished to compare these tools individually and in combination.

*Clinical decision aids*

The scores of clinical decision aids were retrospectively calculated using data prospectively collected as part of the original trial (Supplementary Tables 2, 3, and 4). The HEART score was developed based on clinical experience and medical literature.[5] The T-MACS model was developed using a logistic regression model,[6] and the original model was used because it has been validated for both cardiac troponin T and I.[14] Various GRACE scores were developed to assess immediate and intermediate outcomes in patients with confirmed acute coronary syndrome. The original GRACE score was used, as it is recommended by the European Society of Cardiology guidelines,[15] and a very early invasive strategy was shown to improve clinical outcomes in a subtest of patients with a GRACE score of >140.[16]

*Study outcomes*

The outcomes of interest for the current study were: 1) acute coronary syndrome, including myocardial infarction and unstable angina, during index hospitalisation; and 2) coronary revascularisation within 30 days. Although the diagnosis of acute coronary syndrome and the nature of coronary revascularisation were not centrally adjudicated, the validity of the diagnosis and the necessity of the treatment were determined by treating physicians based on clinical assessment, ECG findings, and results of cardiac troponin testing or other objective investigations.

*Statistical analysis*

Descriptive data were summarised with median (interquartile range) for continuous variables and frequency (percentage) for categorical variables, and differences were compared with the Mann–Whitney *U* test and the Fisher’s exact test as appropriate.

The receiver operating characteristic analysis was conducted, and *C*-statistics of clinical decision aids, CTCA, alone and then each clinical decision aid in combination with CTCA, were compared using the nonparametric method. The performance of clinical decision aids and CTCA in subgroups by age and by sex was explored.

Apart from the overall discrimination and prediction, the performance measures, such as the sensitivity, the specificity, and the negative and the positive predictive value, of each clinical decision aid and CTCA were derived from a two-by-two confusion matrix using cutoffs reported by previously published studies (<4 and >6 for the HEART score, <0.05 and >0.95 for the T-MACS model, <109 and >140 for the GRACE score, and coronary artery anatomy for CTCA). Comparisons were made using the exact McNemar’s test (for sensitivities and specificities) or the weighted generalised score statistics (for negative predictive values and positive predictive values) as appropriate.

A *post hoc* sensitivity analysis using the classification tree analysis, which included all three clinical decision aids and CTCA for tree building, was conducted for both study outcomes. The tree model was developed based on recursive partitioning using the Chi-square automatic interaction detection algorithm (alpha of 0.05 for splitting with the Bonferroni correction) and a 10‐fold cross‐validation for overfitting control. Nodes with a size of ≥10% of the study population size were considered.

This study was exploratory with no adjustment for multiplicity applied. All analyses were performed by the complete-case approach using SAS software, version 9.4 (SAS institute, Cary, NC, USA).

*Patient and public involvement*

The Sheffield Emergency Care Forum (a patient and public representative group that provides independent advice on emergency care related research) provided valuable feedback about the patient perspective throughout the trial, which helped guide the decision making of the trial team. Patients and the public were not directly involved in this secondary analysis.

**Results**

*Study population*

Amongst 1748 patients enrolled in the RAPID-CTCA trial, 974 (56%) were excluded due to the lack of CTCA data, and 75 (4%) were further excluded due to incomplete data for calculation of the three selected clinical decision aids (Figure 1). The study population comprised of 699 patients whose baseline characteristics were similar to those excluded from the analysis (Table 1). At presentation, 155 (22%) patients had a history of myocardial infarction or coronary revascularisation, 283 (40%) had an abnormal ECG, and 404 (58%) had an elevated cardiac troponin concentration.

The median HEART score was 5 (15%, 57%, and 27% had a score of <4, 4–6, and >6), the median T-MACS estimate was 0.26 (19%, 51%, and 30% had an estimate of <0.05, 0.05–0.95, and >0.95), and the median GRACE score was 106 (55%, 32%, and 13% had a score of <109, 109–140, and >140). In addition, 163 (23%), 200 (29%), and 336 (48%) patients had normal coronary arteries, non-obstructive coronary artery disease, and obstructive coronary artery disease respectively.

*Diagnostic performance for the index hospital diagnosis of acute coronary syndrome*

At hospital discharge, 358 (51%) patients had a final diagnosis of acute coronary syndrome. The GRACE score had the lowest discriminative ability for the index hospital diagnosis of acute coronary syndrome, whereas the HEART score, the T-MACS model, and CTCA had better discriminative ability (Figure 2), and the results were comparable across age and sex subgroups (Supplementary Table 5). The T-MACS model (difference in *C*-statistic, 0.03; 95% confidence interval, −0.00 to 0.07; p=0.053) and CTCA (difference in *C*-statistic, 0.06; 95% confidence interval, 0.01 to 0.10; p=0.011) were both more discriminatory than the HEART score.

To further determine the diagnostic performance of the clinical decision aids and CTCA as a ‘rule-out’ tool using the pre-defined ‘low-risk’ threshold, the negative predictive value of CTCA (0.90; 95% confidence interval, 0.84 to 0.94) appeared to be similar to that of the T-MACS model (0.83; 95% confidence interval, 0.76 to 0.89) (p=0.114) but was higher than that of the HEART score (0.81; 95% confidence interval, 0.72 to 0.88) (p=0.032). The T-MACS model (19%) and CTCA (23%) would have excluded acute coronary syndrome in a greater proportion of patients than the HEART score (15%) (p=0.026 and p<0.001 respectively) (Table 2). When being used as a ‘rule-in’ tool with the pre-defined ‘high-risk’ threshold, the positive predictive values of the HEART score, the T-MACS model, and CTCA were similar, and CTCA would have identified a higher proportion of patients with acute coronary syndrome (Supplementary Table 6).

*Prognostic performance for 30-day coronary revascularisation*

The proportion of patients with coronary artery disease on CTCA increased with the estimated risk by clinical decision aid (Supplementary Figure 1). At 30 days, 225 (32%) patients had undergone coronary revascularisation, for which CTCA had the highest *C*-statistic (0.80; 95% confidence interval, 0.77 to 0.83) (Figure 3). Moreover, the results were comparable across age and sex subgroups (Supplementary Table 7). With either the ‘low-risk’ or the ‘high-risk’ threshold, all three clinical decision aids and CTCA had a modest positive predictive value, ranging between 0.26 and 0.58 (Supplementary Table 8). CTCA had the numerically highest negative predictive value—0.96 (95% confidence interval, 0.92 to 0.99) and 0.92 (95% confidence interval, 0.89 to 0.95) in the absence of coronary artery disease and obstructive coronary artery disease respectively, followed by the T-MACS model by the cutoff of 0.05 (0.89; 95% confidence interval, 0.83 to 0.94).

*Performance of clinical decision aids combined with CTCA*

When incorporating each clinical decision aid with CTCA, the diagnostic and prognostic performance of all clinical decision aids improved (Figure 4 and Supplementary Table 9). The combination of the T-MACS model with CTCA was numerically most discriminative for the index hospital diagnosis of acute coronary syndrome and predictive of 30-day coronary revascularisation.

Using the optimal thresholds (a negative predictive value ≥0.99 for ‘rule-out’ and a positive predictive value ≥0.70 for ‘rule-in’) proposed by the European Society of Cardiology, a T-MACS estimate <0.05 and normal coronary arteries on CTCA would have classified 41 (6%) patients ‘rule-out’ for the index hospital diagnosis of acute coronary syndrome, with none having acute coronary syndrome during index hospitalisation or undergoing coronary revascularisation within 30 days. In addition, a T-MACS estimate of ≥0.05 and obstructive coronary artery disease on CTCA or a T-MACS estimate >0.95 and non-obstructive coronary artery disease on CTCA would have classified 299 (43%) patients and 42 (6%) patients ‘rule-in’ for the index hospital diagnosis of acute coronary syndrome respectively. Of these patients, 280 (82%) actually had acute coronary syndrome during index hospitalisation, and 196 (57%) underwent coronary revascularisation within 30 days (Supplementary Table 10).

*Sensitivity analysis*

The classification tree analysis identified the T-MACS estimates and the CTCA findings as the two most important features that discriminated the index hospital diagnosis of acute coronary syndrome (Supplementary Figure 2). The classification algorithm based on the combination of the T-MACS model and CTCA had a negative predictive value of 0.90 (95% confidence interval, 0.85 to 0.93). Similarly, the T-MACS model and CTCA were the two most important risk stratification tools that predicted 30-day coronary revascularisation (Supplementary Figure 3), and the algorithm had a positive predictive value of 0.68 (95% confidence interval, 0.61 to 0.75).

**Discussion**

In this secondary analysis of the RAPID-CTCA trial including only a pre-defined group of patients with intermediate-risk chest pain due to suspected acute coronary syndrome, we demonstrated that the T-MACS model and CTCA had similar but better discriminative ability for the index hospital diagnosis of acute coronary syndrome, compared with the HEART score and the GRACE score. In addition, CTCA, as a single test, was most predictive of 30-day coronary revascularisation. The combination of the T-MACS estimates and the CTCA findings had the best diagnostic and prognostic performance for the index hospital diagnosis of acute coronary syndrome and 30-day coronary revascularisation.

When managing undifferentiated acute chest pain, clinical assessment of presenting symptoms, medical history, and physical examination remain relevant. Experts advocate a sequential approach whereby clinical assessment and ECG findings assist with guiding the appropriate clinical pathway.[17] Whilst clinician judgement continues to be crucial in selecting low-risk patients for early discharge,[18, 19] our findings underline that the structuralised assessment using clinical decision aids or CTCA can be helpful in identifying and managing intermediate-risk patients with suspected acute coronary syndrome.

Compared to algorithms based on high-sensitivity cardiac troponin testing alone, clinical decision aids factoring in additional clinical information achieved a similar safety benchmark to ‘rule out’ myocardial infarction.[20] However, two randomised controlled trials evaluating the HEART score-based management have shown that many patients being considered low-risk still underwent ischaemia investigations,[21, 22] suggesting that physicians and patients often seek reassurance from additional diagnostic testing. Whilst physicians realise that they can rule out myocardial infarction using clinical decision aids, they also understand that this does not equate to the exclusion of underlying coronary artery disease. In the current study, a HEART score of <4 or a T-MACS estimate of <0.05 was associated with coronary artery disease in 44% and 69% of patients respectively. A recent study demonstrated that nearly half of patients with suspected acute coronary syndrome and a very low high-sensitivity cardiac troponin concentration had coronary artery disease.[23] This represents a potential missed opportunity to offer preventative treatment and to improve subsequent outcomes. To that end, CTCA provides anatomical clarification of coronary arteries and refines treatment selection.[24, 25]

Previous studies assessing high-sensitivity troponin testing and clinical decision aids have focused on unselected and predominantly low-risk populations, in which the prevalence of acute coronary syndrome was usually under 20%. The RAPID-CTCA trial enrolled an intermediate-risk patient population, and half of these patients had an index hospital diagnosis of acute coronary syndrome, who represent a real clinical conundrum after initial clinical assessment in terms of whom to select for investigations, invasive coronary angiography, and treatment.[15] We here demonstrated that in the absence of coronary artery disease on CTCA and a T-MACS estimate <0.05, none of these patients had acute coronary syndrome during index hospitalisation or underwent coronary revascularisation within 30 days.

The T-MACS model, compared to the HEART score, tended to have a higher positive predictive value for myocardial infarction,[26] for which further invasive coronary angiography is usually inevitable when trying to establish the diagnosis and guide treatment.[27] On the other hand, CTCA had a high diagnostic accuracy for coronary artery disease,[28] the extent of which remains prognostically important in those with cardiac troponin elevation.[29] Finally, CTCA can identify a new diagnosis that may have not been uncovered by biomarkers or other cardiac imaging.[30]

**Limitations**

Our study has several limitations which we should highlight. First, cardiac troponin was measured locally at each site using different assays and laboratory reference standards to define myocardial infarction, and follow-up cardiac troponin was tested at the discretion of clinicians, which was not systematically recorded in the trial database. Second, the index hospital diagnoses were made by treating physicians rather than independent adjudication. Results of cardiac troponin testing used in risk metrics of all three clinical decision aids could strongly influence such diagnoses, and both cardiac troponin testing and CTCA might have also impacted selection of patients for further investigations, leading to coronary revascularisation. Therefore, we cannot exclude the potential for diagnostic misclassification and bias for incorporation and verification. Third, the HEART score and the T-MACS model were devised as part of initial assessment of undifferentiated acute chest pain to identify low risk patients, and the RAPID-CTCA trial enrolled those at intermediate risk after initial assessment. As a result, the number of patients in our current study with a T-MACS estimate of <0.02 was small, reflecting the higher risk of the population studied in the RAPID-CTCA trial, and therefore we had to use a different threshold (<0.05) to risk stratify patients in this study. Moreover, all clinical decision aids were retrospectively calculated, and some variables, such as the presence of worsening angina, were different from the original validated definition, thereby attenuating their discriminative ability. Finally, patients with inadequate image quality will introduce uncertainty regarding coronary artery anatomy.

**Conclusion**

In intermediate-risk patients with suspected acute coronary syndrome, the T-MACS model and CTCA offered better discrimination for the index hospital diagnosis of acute coronary syndrome, and CTCA provided the best prediction of 30-day coronary revascularisation. Combining the T-MACS estimates with the CTCA findings can enhance diagnosis and management of acute coronary syndrome.

**Funding**

The RAPID-CTCA trial was funded by the UK National Institute for Health and Care Research Health Technology Assessment Programme (13/04/108). The funders played no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.

**Acknowledgements**

The RAPID-CTCA trial was investigator led, and oversight was delivered by a trial management group supported by independent trial steering and data monitoring committees. The RAPID-CTCA trial was coordinated by the Edinburgh Clinical Trials Unit, and governance and monitoring were provided by the Academic and Central Clinical Office for Research and Development on behalf of the trial sponsors (University of Edinburgh and NHS Lothian). CT is supported by the British Heart Foundation (FS/CRTF/21/2473). MM is supported by the British Heart Foundation (FS/CRTF/23/24491). DEN is supported by the British Heart Foundation (CH/09/002, RG/F/22/110093, RE/24/130012) and is the recipient of a Wellcome Trust Senior Investigator Award (WT103782AIA).

**Contributorship statement**

Concept and design: WKL and CT.

Analysis or interpretation of data: WKL, CT, MM, DEN, and AJG.

Drafting of the manuscript: WKL, DEN, and AJG.

Critical revision of the manuscript for important intellectual content: CT, MM, RO, KO, LK, RFS, DF, NC, AK, CR, JES, and SG.

Obtained funding: DEN and AJR.

Administrative, technical, or material support: RO and KO.

Supervision: LK, RFS, DF, NC, AK, CR, JES, SG, DEN, and AJR.

**References**

1 Schiele F, Aktaa S, Rossello X, et al. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. *Eur Heart J Acute Cardiovasc Care* 2021;**10**:224-33.

2 Chiang CH, Chiang CH, Pickering JW, et al. Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction : An International Collaborative Meta-analysis. *Ann Intern Med* 2022;**175**:101-13.

3 Twerenbold R, Neumann JT, Sorensen NA, et al. Prospective Validation of the 0/1-h Algorithm for Early Diagnosis of Myocardial Infarction. *J Am Coll Cardiol* 2018;**72**:620-32.

4 Chiang CH, Chiang CH, Lee GH, et al. Safety and efficacy of the European Society of Cardiology 0/1-hour algorithm for diagnosis of myocardial infarction: systematic review and meta-analysis. *Heart* 2020;**106**:985-91.

5 Backus BE, Six AJ, Kelder JC, et al. A prospective validation of the HEART score for chest pain patients at the emergency department. *Int J Cardiol* 2013;**168**:2153-8.

6 Body R, Carlton E, Sperrin M, et al. Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts. *Emerg Med J* 2017;**34**:349-56.

7 Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. *Arch Intern Med* 2003;**163**:2345-53.

8 Nestelberger T, Wildi K, Boeddinghaus J, et al. Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0h/1h-algorithm for the early diagnosis of acute myocardial infarction. *Int J Cardiol* 2016;**207**:238-45.

9 Chew DP, Lambrakis K, Blyth A, et al. A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes: The Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High-Sensitivity Troponin T Study (RAPID-TnT). *Circulation* 2019;**140**:1543-56.

10 Meier M, Boeddinghaus J, Nestelberger T, et al. Comparing the utility of clinical risk scores and integrated clinical judgement in patients with suspected acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care* 2023;**12**:693-702.

11 Wang KL, Meah MN, Bularga A, et al. Computed tomography coronary angiography in non-ST-segment elevation myocardial infarction. *Br J Radiol* 2022;**95**:20220346.

12 Ueng KC, Chiang CE, Chao TH, et al. 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome. *Acta Cardiol Sin* 2023;**39**:4-96.

13 Gray AJ, Roobottom C, Smith JE, et al. Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. *BMJ* 2021;**374**:n2106.

14 Va Den Berg P, Burrows G, Lewis P, et al. Validation of the (Troponin-only) Manchester ACS decision aid with a contemporary cardiac troponin I assay. *Am J Emerg Med* 2018;**36**:602-7.

15 Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J Acute Cardiovasc Care* 2024;**13**:55-161.

16 Kofoed KF, Kelbaek H, Hansen PR, et al. Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. *Circulation* 2018;**138**:2741-50.

17 Writing C, Kontos MC, de Lemos JA, et al. 2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2022;**80**:1925-60.

18 Reinhardt SW, Lin CJ, Novak E, et al. Noninvasive Cardiac Testing vs Clinical Evaluation Alone in Acute Chest Pain: A Secondary Analysis of the ROMICAT-II Randomized Clinical Trial. *JAMA Intern Med* 2018;**178**:212-9.

19 Twerenbold R, Costabel JP, Nestelberger T, et al. Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction. *J Am Coll Cardiol* 2019;**74**:483-94.

20 Steiro OT, Tjora HL, Langorgen J, et al. Clinical risk scores identify more patients at risk for cardiovascular events within 30 days as compared to standard ACS risk criteria: the WESTCOR study. *Eur Heart J Acute Cardiovasc Care* 2021;**10**:287-301.

21 Mahler SA, Riley RF, Hiestand BC, et al. The HEART Pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge. *Circ Cardiovasc Qual Outcomes* 2015;**8**:195-203.

22 Poldervaart JM, Reitsma JB, Backus BE, et al. Effect of Using the HEART Score in Patients With Chest Pain in the Emergency Department: A Stepped-Wedge, Cluster Randomized Trial. *Ann Intern Med* 2017;**166**:689-97.

23 Lee KK, Bularga A, O'Brien R, et al. Troponin-Guided Coronary Computed Tomographic Angiography After Exclusion of Myocardial Infarction. *J Am Coll Cardiol* 2021;**78**:1407-17.

24 Wang KL, Roobottom C, Smith JE, et al. Presentation cardiac troponin and early computed tomography coronary angiography in patients with suspected acute coronary syndrome: a pre-specified secondary analysis of the RAPID-CTCA trial. *Eur Heart J Acute Cardiovasc Care* 2022;**11**:570-9.

25 Wang KL, Meah MN, Bularga A, et al. Early computed tomography coronary angiography and preventative treatment in patients with suspected acute coronary syndrome: A secondary analysis of the RAPID-CTCA trial. *Am Heart J* 2023;**266**:138-48.

26 Body R, Morris N, Reynard C, et al. Comparison of four decision aids for the early diagnosis of acute coronary syndromes in the emergency department. *Emerg Med J* 2020;**37**:8-13.

27 Chao TH, Yeh HI, Shyu KG, et al. Rationale and Study Design of the TSOC-Fully Organized Registry for the Management of Symptomatic ACS Study (T-FORMOSA Study). *Acta Cardiol Sin* 2023;**39**:561-71.

28 Linde JJ, Kelbaek H, Hansen TF, et al. Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. *J Am Coll Cardiol* 2020;**75**:453-63.

29 Kofoed KF, Engstrom T, Sigvardsen PE, et al. Prognostic Value of Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. *J Am Coll Cardiol* 2021;**77**:1044-52.

30 Meah MN, Wereski R, Bularga A, et al. Coronary low-attenuation plaque and high-sensitivity cardiac troponin. *Heart* 2023;**109**:702-9.

**Figure legends**

**Figure 1. Study flowchart.**

CTCA = computed tomography coronary angiography; ECG = electrocardiogram

**Figure 2. Receiver operating characteristic analysis for index hospital diagnosis of acute coronary syndrome.**

CI = confidence interval; CTCA = computed tomography coronary angiography

**Figure 3. Receiver operating characteristic analysis for 30-day coronary revascularisation.**

CI = confidence interval; CTCA = computed tomography coronary angiography

**Figure 4. Receiver operating characteristic analysis of the combination of clinical decision aids and CTCA for (A) index hospital diagnosis of acute coronary syndrome and (B) 30-day coronary revascularisation.**

CI = confidence interval; CTCA = computed tomography coronary angiography

|  |
| --- |
| **Table 1. Baseline characteristics of patients included in and excluded from the analysis.** |
|  | **Included in analysis****(N = 699)** | **Excluded from analysis****(N = 1049)** | **p value** |
| Age, years | 61 (53 to 71) | 61 (52 to 71) | 0.924 |
| Female sex | 261 (37) | 373 (36) | 0.447 |
| Diabetes mellitus | 115 (16) | 203 (19) | 0.129 |
| Hypertension | 313 (45) | 504 (48) | 0.187 |
| Dyslipidaemia | 285 (41) | 409 (39) | 0.485 |
| Former or current smoker | 416 (60) | 645 (61) | 0.424 |
| Prior myocardial infarction or coronary revascularisation | 155 (22) | 268 (26) | 0.111 |
| Clinical gestalt for acute coronary syndrome |  |  | 0.928 |
|  Low suspicion | 127 (18) | 187 (18) |  |
|  Moderate suspicion | 319 (46) | 473 (45) |  |
|  High suspicion | 253 (36) | 389 (37) |  |
| ECG at presentation |  |  | 0.841 |
|  Normal | 257 (37) | 391 (38) |  |
|  Non-ischaemic | 159 (23) | 242 (23) |  |
|  Ischaemic | 283 (40) | 406 (39) |  |
| Cardiac troponin at presentation |  |  | 0.684 |
|  ≤99th centile upper reference limit | 295 (42) | 380 (41) |  |
|  >99th centile upper reference limit | 404 (58) | 545 (59) |  |
| HEART score | 5 (4 to 7) | 5 (4 to 6) | 0.826 |
| T-MACS estimate | 0.26 (0.08 to 0.98) | 0.32 (0.08 to 1.00) | 0.547 |
| GRACE score | 106 (89 to 125) | 105 (90 to 124) | 0.997 |
| CTCA finding |  |  | 0.192 |
|  Normal coronary arteries | 163 (23) | 22 (29) |  |
|  Non-obstructive coronary artery disease | 200 (29) | 25 (33) |  |
|  Obstructive coronary artery disease | 336 (48) | 28 (37) |  |
| \* Values are median (interquartile range) or n (%).† Non-ischaemic ECG includes other abnormalities, bundle branch block, and left ventricular hypertrophy, and ischaemic ECG includes T-wave inversion and ST-segment deviation.CTCA = computed tomography coronary angiography; ECG = electrocardiogram |

|  |
| --- |
| **Table 2. Performance metrics for index hospital diagnosis of acute coronary syndrome using ‘low-risk’ thresholds.** |
|  | **Sensitivity (95% confidence interval)** | **Specificity (95% confidence interval)** | **Negative predictive value (95% confidence interval)** | **Positive predictive value (95% confidence interval)** | **No. considered low risk** |
| HEART score | 0.94 (0.92 to 0.97) | 0.25 (0.21 to 0.30) | 0.81 (0.72 to 0.88) | 0.57 (0.53 to 0.61) | 106 (15) |
| T-MACS model | 0.94 (0.91 to 0.96) | 0.33 (0.28 to 0.38) | 0.83 (0.76 to 0.89) | 0.59 (0.55 to 0.63) | 133 (19) |
| GRACE score | 0.52 (0.47 to 0.57) | 0.62 (0.56 to 0.67) | 0.55 (0.50 to 0.60) | 0.59 (0.53 to 0.64) | 382 (55) |
| CTCA | 0.95 (0.93 to 0.97) | 0.43 (0.37 to 0.48) | 0.90 (0.84 to 0.94) | 0.64 (0.59 to 0.68) | 163 (23) |
| \* ‘Low-risk’ thresholds are a HEART score of 4, a T-MACS estimate of 0.05, a GRACE score of 109, and coronary artery disease on CTCA.CTCA = computed tomography coronary angiography |